“…In fact, several HDAC inhibitors have been applied for treatment of T-cell lymphoma, such as SAHA (suberoylanilide hydroxamic acid, Vorinostat) (Negmeldin and Pflum, 2017) and Belinostat (Poole, 2014), and Panobinostat (Garnock-Jones, 2015). Unfortunately, these FDA approved drugs are relatively non-selective and inhibit most of the zincdependent HDAC subtypes (Yang, 2011;Qiao et al, 2013), which could cause several mild or severe toxic effects associated with the treatment, such as dehydration, thrombocytopenia, anorexia, and cardiac arrhythmia (Chakrabarti et al, 2016;Buonvicino et al, 2018;Cosenza and Pozzi, 2018;Laino et al, 2019). In addition, due to the physicochemical properties of hydroxamic acid group as the ZBG, some drawbacks have been exposed, including poor stability, easy metabolism, weak binding ability to class IIa isozymes, and poor selectivity, making the design and discovery of HDAC inhibitors with novel zinc binding group (ZBG) more necessary (Di Micco et al, 2008;Botta et al, 2011;Burli et al, 2013;Zhao et al, 2018;Banerjee et al, 2019).…”